复星医药(02196.HK) 表示，近日内部发布了自主研发的PharmAID决策智能体平台，目前是构建覆盖创新研发场景的全生命周期智能决策网络。该平台深度融合全球领先的大模型技术，具备AI翻译、AI医学写作/修订等功能，并已率先接入Deepseek R1及全球多个专业临床资讯及管线数据平台，令医药健康领域内容生成准确率较通用大模型提升50%，而且数据为“T+1”更新。
基于PharmAID决策智能体平台，复星医药正加速推进“药物商业价值辅助决策”的能力建设，提升决策视野及决策准确性，期望可打造医药行业首个AI决策智能体平台。(gc/da)(港股报价延迟最少十五分钟。沽空资料截至 2025-02-14 16:25。)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.